论文部分内容阅读
目的:探索干扰素α-2b联合扶正化瘀胶囊治疗乙型病毒性肝炎的疗效。方法:将80例乙型病毒性肝炎患者随机分为治疗组和对照组,治疗组给予干扰素α-2b联合扶正化瘀胶囊治疗,对照组给予干扰素α-2b治疗,分别于治疗后3、6、12个月检测血常规、肝功能,并观察疗效。结果:12个月后,治疗组疗效、HBV、DNA阴转率均优于对照组,不良反应发生率低于对照组,差异有统计学意义(P﹤0.05)。结论:干扰素α-2b联合扶正化瘀胶囊治疗乙型病毒性肝炎疗效优于单纯干扰素α-2b治疗。
Objective: To explore the efficacy of interferon α-2b combined with Fuzhenghuayu capsule in the treatment of hepatitis B virus. Methods: Eighty patients with viral hepatitis B were randomly divided into treatment group and control group. The treatment group was treated with interferon alfa-2b combined with Fuzhenghuayu capsule and the control group with interferon alpha-2b treatment. After treatment, , 6,12 months of blood tests, liver function, and observe the effect. Results: After 12 months, the efficacy of the treatment group, HBV, DNA negative conversion rate were better than the control group, the incidence of adverse reactions was lower than the control group, the difference was statistically significant (P <0.05). Conclusion: Interferon α-2b combined with Fuzhenghuayu Capsule is superior to interferon α-2b in the treatment of hepatitis B virus.